SecBot SecBot
Biotech Drug Report Generated Nov 8, 2026

ELEVIDYS

SRPT·Sarepta Therapeutics, Inc.
MIXED
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available in the U.S. for ambulatory Duchenne patients. Expansion to non-ambulatory patients is uncertain after the ENVISION trial closure; a safety study and FDA engagement in Q1 2027 will determine the path forward.
Why 4/10
ELEVIDYS is already approved and commercialized with no pending PDUFA or pivotal readout. The next hard catalyst is the Q1 2027 FDA engagement on the non-ambulatory safety study, roughly 4-5 months out, but this is a regulatory discussion rather than a binary approval decision. The drug is a major revenue driver for Sarepta, but the company also has an exon-skipping franchise, so concentration is not total. Per the rubric, an approved drug with no imminent new regulatory decision scores 3-5.
Actionable Insight MIXED

Watch for the Q1 2027 FDA engagement on the sirolimus safety study for non-ambulatory patients. A constructive outcome could open a path to label expansion and de-risk the safety narrative, while a negative FDA response would reinforce concerns about ELEVIDYS' risk profile and limit its addressable market. Also monitor quarterly revenue trends for signs of stabilization or further erosion in the approved ambulatory population.

Price Chart

Loading chart...

Executive Summary

ELEVIDYS (delandistrogene moxeparvovec) is Sarepta Therapeutics' FDA-approved one-time gene therapy for Duchenne muscular dystrophy. It generated significant revenue but faces serious headwinds: three patient deaths led to closure of the ENVISION Phase 3 trial in non-ambulatory patients, the FDA added a black-box warning for acute liver injury in August 2026, and the company had a public dispute with the FDA in July 2025 over shipping the drug. The stock trades near $18, down from a 52-week high of $24.68, with a mixed analyst consensus (12 buy/strong buy, 13 hold, 6 sell/strong sell). The next catalyst is a Q1 2027 FDA engagement on a safety study for non-ambulatory patients.

How It Works

A one-time gene therapy given as an intravenous infusion. It uses a harmless virus (AAV) to deliver a working copy of a shortened but functional version of the dystrophin gene (called micro-dystrophin) directly into muscle cells. Boys with Duchenne muscular dystrophy lack functional dystrophin, which causes progressive muscle degeneration. The therapy aims to restore enough dystrophin production to slow or halt disease progression.

Trial Status

ELEVIDYS received accelerated FDA approval in June 2023 for ambulatory boys aged 4-5 with DMD, followed by traditional approval with an expanded label in June 2024 covering a broader ambulatory population. The confirmatory ENVISION Phase 3 trial in non-ambulatory patients was closed in November 2026 after three patient deaths linked to acute liver failure. Sarepta is now planning a 25-patient safety study combining ELEVIDYS with the immunosuppressant sirolimus, with FDA engagement expected in Q1 2027. New data presented at the 2026 World Muscle Society congress showed durable functional benefit in older ambulatory patients (ages 8-12) over two years versus external controls.

The Two-Sided Case

▲ Bull Case5
ELEVIDYS is the only approved gene therapy for Duchenne muscular dystrophy, a large unmet-need market with no cure, giving Sarepta a first-mover advantage.
New data from the 2026 World Muscle Society congress showed durable and clinically meaningful functional benefit in older ambulatory patients (ages 8-12) over two years versus external controls, supporting the approved label.
Sarepta raised the low end of its 2026 total net product revenue guidance by $50 million to a range of $1.25-$1.3 billion, signaling confidence in the commercial franchise including ELEVIDYS.
Institutional accumulation continued in Q2 and Q3 2026, with BlackRock adding 28.7%, Goldman Sachs adding 89.4%, and State Street adding 34.8% to their positions.
The analyst consensus mean price target of $21.64 implies roughly 21% upside from the current ~$17.82 share price.
▼ Bear Case5
The ENVISION Phase 3 trial in non-ambulatory patients was closed after three patient deaths from acute liver failure, a major safety setback that raises questions about the therapy's risk profile.
The FDA added a black-box warning for acute serious liver injury and acute liver failure to the ELEVIDYS label in August 2026, the strongest possible safety warning.
In July 2025, the FDA asked Sarepta to voluntarily stop shipping ELEVIDYS; Sarepta refused, and the stock fell 36% in a single day, damaging management credibility with regulators.
ELEVIDYS sales declined year-over-year in Q2 2026 (down 34% to $401.3M) and Q3 2026 revenue of $381.35M missed analyst estimates, with the label update cited as a factor.
Competition is closing in as other Duchenne gene therapy programs advance, and the path to expanding the label to non-ambulatory patients is now uncertain after the ENVISION trial failure.

Upcoming Catalysts

  • Q1 2027: FDA engagement on the 25-patient sirolimus safety study for non-ambulatory Duchenne patients
  • Ongoing commercial execution and quarterly revenue reports for ELEVIDYS in the approved ambulatory indication

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sarepta Therapeutics, Inc. 8-K SRPT ·Originating report

Sources · 8

Hover a chip for the title
1 msn.com2 biospace.com3 msn.com4 businesswire.com5 reuters.com6 seekingalpha.com7 morningstar.com8 seekingalpha.com